Amneal Pharmaceuticals, Inc. (AMRX)
AMRX Stock Price Chart
Explore Amneal Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze AMRX price movements and trends.
AMRX Company Profile
Discover essential business fundamentals and corporate details for Amneal Pharmaceuticals, Inc. (AMRX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
7 May 2018
Employees
8.30K
Website
https://www.amneal.comCEO
Chirag K. Patel
Description
Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, promotion, distribution, and sale of branded pharmaceutical products with focus on central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers Emverm, a chewable tablet for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; Rytary to treat Parkinson's disease; and Unithroid for the treatment of hypothyroidism. The AvKARE segment provides pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. It is also involved in the wholesale distribution of bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names, as well as medical and surgical products; and packaging and wholesale distribution of pharmaceuticals and vitamins to its retail and institutional customers. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It operates in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
AMRX Financial Timeline
Browse a chronological timeline of Amneal Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Apr 2026
Upcoming earnings on 27 Feb 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is $0.15.
Earnings released on 5 Aug 2025
EPS came in at $0.25 surpassing the estimated $0.18 by +38.89%, while revenue for the quarter reached $724.51M , missing expectations by -5.68%.
Earnings released on 2 May 2025
EPS came in at $0.21 surpassing the estimated $0.15 by +40.00%, while revenue for the quarter reached $695.42M , missing expectations by -6.56%.
Earnings released on 28 Feb 2025
EPS came in at $0.12 falling short of the estimated $0.15 by -20.00%, while revenue for the quarter reached $730.52M , beating expectations by +1.03%.
Earnings released on 8 Nov 2024
EPS came in at $0.16 surpassing the estimated $0.13 by +23.08%, while revenue for the quarter reached $702.47M , beating expectations by +0.23%.
Earnings released on 9 Aug 2024
EPS came in at $0.16 surpassing the estimated $0.14 by +14.29%, while revenue for the quarter reached $701.78M , beating expectations by +6.63%.
Earnings released on 3 May 2024
EPS came in at $0.14 surpassing the estimated $0.09 by +55.56%, while revenue for the quarter reached $659.19M .
Earnings released on 1 Mar 2024
EPS came in at $0.14 surpassing the estimated $0.07 by +100.00%, while revenue for the quarter reached $616.98M , missing expectations by -7.02%.
Earnings released on 7 Nov 2023
EPS came in at $0.19 surpassing the estimated $0.12 by +58.33%, while revenue for the quarter reached $620.04M , missing expectations by -2.24%.
Earnings released on 4 Aug 2023
EPS came in at $0.19 surpassing the estimated $0.10 by +90.00%, while revenue for the quarter reached $599.05M , beating expectations by +5.95%.
Earnings released on 5 May 2023
EPS came in at $0.12 surpassing the estimated $0.09 by +33.33%, while revenue for the quarter reached $557.54M , beating expectations by +3.77%.
Earnings released on 2 Mar 2023
EPS came in at $0.23 surpassing the estimated $0.21 by +9.52%, while revenue for the quarter reached $609.76M , beating expectations by +8.47%.
Earnings released on 4 Nov 2022
EPS came in at $0.14 falling short of the estimated $0.18 by -22.22%, while revenue for the quarter reached $545.56M .
Earnings released on 5 Aug 2022
EPS came in at $0.19 falling short of the estimated $0.20 by -5.00%, while revenue for the quarter reached $559.36M .
Earnings released on 4 May 2022
EPS came in at $0.12 matching the estimated $0.12, while revenue for the quarter reached $497.63M , missing expectations by -7.14%.
Earnings released on 2 Mar 2022
EPS came in at $0.18 falling short of the estimated $0.19 by -5.26%, while revenue for the quarter reached $536.90M , beating expectations by +6.89%.
Earnings released on 3 Nov 2021
EPS came in at $0.21 surpassing the estimated $0.20 by +5.00%, while revenue for the quarter reached $528.59M , missing expectations by -2.92%.
Earnings released on 9 Aug 2021
EPS came in at $0.25 surpassing the estimated $0.18 by +38.89%, while revenue for the quarter reached $535.08M , meeting expectations.
Earnings released on 7 May 2021
EPS came in at $0.20 surpassing the estimated $0.18 by +11.11%, while revenue for the quarter reached $493.11M , beating expectations by +12.50%.
Earnings released on 26 Feb 2021
EPS came in at $0.14 surpassing the estimated $0.13 by +7.69%, while revenue for the quarter reached $510.03M , meeting expectations.
Earnings released on 6 Nov 2020
EPS came in at $0.16 surpassing the estimated $0.13 by +23.08%, while revenue for the quarter reached $519.29M , beating expectations by 0.00%.
AMRX Stock Performance
Access detailed AMRX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.